[ARCHIVE]2026-06-18T18:02:33.041723+00:00
Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call - Relmada Therapeutics (NASDAQ:RLMD)
Executive Summary
HC Wainwright initiates Relmada Therapeutics (NASDAQ: RLMD) with a Buy rating and $12 target, highlighting its bladder cancer potential.
Deep analysis unavailable for this source.
View Original SourceClassification: Open